This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.10.082v1 49/21/2120    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Imai, M. Articles by Sabbah, H. N. Search for Related Content PubMed Articles by Imai, M. Articles by Sabbah, H. N.

PRECLINICAL STUDY

Therapy With Cardiac Contractility Modulation Electrical Signals Improves Left Ventricular Function and Remodeling in Dogs With Chronic Heart Failure

Makoto Imai, MD^_*, Sharad Rastogi, MD^_*, Ramesh C. Gupta, PhD^_*, Sudhish Mishra, PhD^_*, Victor G. Sharov, MD, PhD^_*, William C. Stanley, PhD, Yuval Mika, PhD, Benny Rousso, PhD, Daniel Burkhoff, MD, PhD, FACC, Shlomo Ben-Haim, MD, PhD and Hani N. Sabbah, PhD, FACC^_*,_*

^_* Division of Cardiovascular Medicine, Henry Ford Heart and Vascular Institute, Detroit, Michigan
Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, Ohio
Impulse Dynamics USA, Inc., Orangeburg, New York.

Manuscript received August 11, 2006; accepted October 1, 2006.

^_* Reprint requests and correspondence: Dr. Hani N. Sabbah, Cardiovascular Research, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, Michigan 48202. (Email: HSABBAH1{at}hfhs.org).

Objectives: This study examined the effects of long-term delivery of cardiac contractility modulation (CCM) electric signals on left ventricular (LV) function and global, cellular, and molecular remodeling in dogs with chronic heart failure (HF).

Background: Acute studies in dogs with experimentally induced HF showed that CCM signals applied to the failing myocardium during the absolute refractory period improved LV function without increasing myocardial oxygen consumption.

Methods: In one study, dogs with intracoronary microembolization-induced HF were randomized to 3 months of active CCM monotherapy or to a sham-operated control group. In another study, 19 HF dogs were randomized to 3 months chronic monotherapy with extended release metoprolol succinate (MET-ER), MET-ER with CCM, or no therapy at all (control group).

Results: In CCM-only treated dogs, LV ejection fraction (EF) increased (27 ± 1% vs. 33 ± 1%, p < 0.0001) compared with a decrease in sham-operated control animals (27 ± 1% vs. 23 ± 1%, p < 0.001). The increase in EF seen with CCM-treated dogs was accompanied by reduced LV volumes, improved myocardial structure, reversal of the maladaptive fetal gene program, and an improvement in sarcoplasmic reticulum calcium cycling proteins. Dogs treated with a combination of MET-ER and CCM showed a greater increase in LV EF and a greater reversal of LV global, structural, and biochemical remodeling compared with dogs treated with MET-ER alone.

Conclusions: In dogs with HF, long-term CCM therapy improves LV systolic function. The improvements are additive to those seen with beta-blockers. These findings are further strengthened by the concomitant benefits of CCM therapy on LV global, cellular, and biochemical remodeling.

Abbreviations and Acronyms   ANP = atrial natriuretic peptide   AR = adrenergic receptor   BNP = brain natriuretic peptide   CCM = cardiac contractility modulation   CD = capillary density   CSQ = calsequestrin   EDV = left ventricular end-diastolic volume   EF = ejection fraction   ESV = end-systolic volume   GAPDH = glyceraldehyde-3-phosphate dehydrogenase   HF = heart failure   LV = left ventricular   MCSA = myocyte cross-sectional area   MET-ER = metoprolol succinate-extended release   MHC = -myosin heavy chain   MVO2 = myocardial oxygen consumption   ODD = oxygen diffusion distance   PLB = phospholamban   P-PLB = phosphorylated phospholamban   RyR = ryanodine receptor   SERCA-2a = sarcoplasmic reticulum calcium ATPase   SR = sarcoplasmic reticulum   VFIF = volume fraction of interstitial fibrosis   VFRF = volume fraction of replacement fibrosis

This article has been cited by other articles:

				J. A. Dixon and F. G. Spinale Large Animal Models of Heart Failure: A Critical Link in the Translation of Basic Science to Clinical Practice Circ Heart Fail, May 1, 2009; 2(3): 262 - 271. [Abstract] [Full Text] [PDF]

				H. Nagele, S. Behrens, and C. Eisermann Cardiac contractility modulation in non-responders to cardiac resynchronization therapy Europace, December 1, 2008; 10(12): 1375 - 1380. [Abstract] [Full Text] [PDF]

				S. Rastogi, V. G. Sharov, S. Mishra, R. C. Gupta, B. Blackburn, L. Belardinelli, W. C. Stanley, and H. N. Sabbah Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2149 - H2155. [Abstract] [Full Text] [PDF]

				C. Butter, S. Rastogi, H.-H. Minden, J. Meyhofer, D. Burkhoff, and H. N. Sabbah Cardiac Contractility Modulation Electrical Signals Improve Myocardial Gene Expression in Patients With Heart Failure J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1784 - 1789. [Abstract] [Full Text] [PDF]

				J. C. Daubert Modulation of cardiac contractility. A potential treatment of heart failure? Eur. Heart J., April 2, 2008; 29(8): 961 - 963. [Full Text] [PDF]

				M. M. Borggrefe, T. Lawo, C. Butter, H. Schmidinger, M. Lunati, B. Pieske, A. R. Misier, A. Curnis, D. Bocker, A. Remppis, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure Eur. Heart J., April 2, 2008; 29(8): 1019 - 1028. [Abstract] [Full Text] [PDF]

				C. Butter, J. Meyhofer, M. Seifert, M. Neuss, and H.-H. Minden First use of cardiac contractility modulation (CCM) in a patient failing CRT therapy: Clinical and technical aspects of combined therapies Eur J Heart Fail, September 1, 2007; 9(9): 955 - 958. [Abstract] [Full Text] [PDF]